DART Yields Robust Survival Benefit vs Standard of Care in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced good quality of life and promising survival benefit after being treated with de-escalated adjuvant radiation therapy.

Treatment with de-escalated adjuvant radiation therapy (DART) resulted in robust responses in a population of patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma compared with standard of care adjuvant treatment, according to findings from the phase 3 MC1675 trial (NCT02908477) presented at the 2021 American Society for Radiation Oncology Annual Meeting. However, caution should be used when de-escalating patients with extranodal extension (ENE)–positive pN2 disease.

Patients treated in the standard-of-care arm experienced a 2-year overall survival (OS) rate of 97.0% (95% CI, 91.3%-100%) versus 96.1% (95% CI, 92.3%-100%) in the DART arm. In patients who were ENE–negative disease, the 2-year OS rates were 90.9% (95% CI, 75.4%-100%) and 100% (95% CI, 100%-100%) in the standard of care and DART arms, respectively. Conversely, patients with ENE-positive disease experienced corresponding OS rates of 100% (95% CI, 100%-100%) and 93.4% (95% CI, 87.3%-100%).

“DART demonstrated less toxicity, improved swallowing function, and quality of life [QoL] compared with standard of care. DART also [resulted in] excellent locoregional control, progression-free survival [PFS], and OS rates, particularly in the ENE-negative cohort,” according to lead author Daniel Ma, MD, a head and neck radiation oncologist in the Department of Radiation Oncology at Mayo Clinic in Rochester, Minnesota. “Our future work will define risk groups that may not [respond to] adjuvant care, ones that may require DART, and ones that require full systemic treatment or possibly even systemic intensification.”

Investigators enrolled 194 patients with p16-positive oropharyngeal squamous cell carcinoma whose disease was resectable by transoral robotic surgery (TORS). Patients with T3N2 disease or higher and either lymphovascular or perineural invasion were stratified to cohort A (n = 79) and those with ENE-positivity were stratified to cohort B (n = 115). Patients in cohort A were either treated with 30 Gy of radiation, including 1.5 Gy twice a day for days 1 to 5 and 8 to 12 plus 15 mg/m2 docetaxel on days 1 and 8 (n = 53) or 60 Gy in 2 Gy fractions (n = 26). Patients in cohort B received either 36 Gy of radiation, including 1.8 Gy twice daily on days 1 to 5 and 8 to 12 plus 15 mg/m2 of docetaxel on days 1 and 8 (n = 77), or 60 Gy in 2 Gy fractions plus 40 mg/m2 of cisplatin weekly (n = 38).

The study’s primary end point was rate of adverse effects (AEs) of grade 3 or higher 3 months or more following radiotherapy, with key secondary end points including OS, local/regional control (LRC), and PFS.

Patients had a median age of 59.4 years, and the majority were male (89%) and non-smokers (72%). The study had a median follow-up of 25.3 months.

Additional findings from the study indicated that patients in the standard-of-care and DART arms experienced 2-year locoregional recurrence–free survival (LRFS) rates of 97.9% and 95.5%, respectively. Patients in the standard of care arm had a 2-year PFS rate of 95.1% compared with 86.5% in the DART arm.

Among patients with pN2 disease, those in the standard-of-care and DART arms had 30-month PFS rates of 100% and 42.9%, respectively. Patients in both groups had a distant metastasis–free survival rate of 100% and 59.4%, respectively. Similarly, those in the standard-of-care arm had an LRC rate of 100% versus 77.0% in the DART arm.

Moreover, in terms of locoregional control, patients with ENE-negative disease who received standard of care had a 2-year LRFS rate of 93.3% compared with 100% in the DART arm. Patients with ENE-positivity experienced LRFS rates of 100% and 92.2% in each treatment arm, respectively.

Investigators did not report any grade 5 post-operative AEs. The post-operative TORS interventional bleed rate was 3.2%. A total of 1.6% of patients in the DART arm and 27.4% of patients in the standard-of-care arm (P <.0001) required the use of a feeding tube. Investigators also reported that 1.6% of patients in the DART arm and 7.1% of patients in the standard of care arm (P = .058) experienced AEs of grade 3 or higher 3 months following treatment.

It was also noted that swallowing function following radiotherapy was superior in those who received DART (Modified Barium Swallow Impairment Profile, -0.3 vs -2.6; P = .0155). Moreover, patients treated with DART had a better QOL, less pain, and less xerostomia compared with the standard of care arm.


Ma DJ, Price K, Moore EJ, et al. MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma. Int J Radia Oncol Biol Phys. 2021;111(3):S61. doi:10.1016/j.ijrobp.2021.07.155

Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.